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Background and Objective: The frequency of very late stent thrombosis
(VLST) up to 3 years after Sirolimus-Eluting Stent (SES) implantation is 0.5%
to 0.6%/year, but the rate after 3 years (“very” VLST) is not known.
Methods: Diabetic and non-diabetic patients, with or without multiple dis-
eased vessels, included in the EVASTENT matched cohort registry were fol-
lowed-up 5½ years or more after stent implantation.
Results: Follow-up was obtained in 92% of the cohort (median 5.6 years).
All cause deaths (including cancer and complications of diabetes), at a steady
rate of 2.5%/year up to 3 years, continued at 1.2%/year beyond 3 years (dif-
ference NS). In contrast VLST (any ARC definition) was only 0.18%/year
(95% Confidence interval: 0.08-0.39) after 3 years, versus 0.63%/year (CI:
0.41 to - 0.98) between 1 and 3 years (p=0.03). Target lesion revascularisation
(TLR) was also lower after 3 years than before 3 years (1.9% vs.7%, p0.01),
66% of the revascularization procedures after 3 years being for non-target
lesions. After 3 years,. in contrast to that before 3 years, no differences
between db+ and db– were observed for TLR and ST rates. It is noteworthy
that 51% of patients continued to be on clopidogrel therapy 6 years after
receiving one or more SES.
Conclusion: All cause deaths continued at a steady rate over 6 years, in
particular in the diabetic groups with multiple pathologies, reflecting the
increased age of the population. However cardiac deaths and “very” VLST
leveled out beyond 3 years.
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Aim: To compare clinical outcomes in consecutive patients treated by per-
cutaneous coronary intervention (PCI) according to the type of stent used: 1)
BMS vs. DES, 2) Sirolimus- (SES) vs. Paclitaxel- (PES) vs. Zotarolimus-
(ZES) vs. Everolimus eluting stent (EES).
Methods: Among 2334 PCI performed over two years, consecutive
patients treated successfully with only one kind of stent were included.
Patients with MI, cardiogenic shock or out-of-hospital cardiac arrest were
excluded. 
We compare the occurrence of 1) TVF (CV death, Target vessel MI, TVR),
2) Target Lesion Revascularization (TLR) and 3) definite Stent Thrombosis
(ST) at one year. 
Results: Twelve hundred sixty patients fulfilled inclusion criteria, 615
(49%) had BMS, 645 (51%) DES. Among the DES group, 187 (29%) had
SES, 171 (27%) PES, 206 (32%) ZES, 67 (10%) EES and 14 (2%) others.
Patients in the BMS group were older, had more comorbidities, the mean
stent length was lower and the average stent diameter higher, compared to
DES.
Clinical and procedural characteristics were well matched between the dif-
ferent type of DES, except for a lower mean and total stent length in the PES
group,
TVF according to the type of stent are shown in the figure. TLR was
higher after BMS implantation (9.9% vs. 4.3%, p=0.002) without any differ-
ence between the different type of DES. The definite ST rates were compa-
rable whatever the stent used. 
Independent predictors of TVF were BMS (OR 2.089; 95%CI 1.345-3.115,
p<0.001), EES (OR 0.127; 95%CI 0.017-0.956, p=0.045) as hypertension,
prior PCI and renal failure.
Conclusions: In ‘real life’, BMS is independently correlated with an
excess of TVF, only partly explained by the higher risk feature of the popula-
tion. All kind of DES are similarly associated with a lower TLR rate without
any excess of stent thrombosis at one year. EES appears independently asso-
ciated with the absence of TVF.
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Background: Drug-eluting stents (DES) are more effective than bare-
metal stents (BMS) in the treatment of small coronary vessel lesion. There are
limited data on the safety and efficacy of DES in this indication in elderly
patients. We aimed to assess the long-term clinical outcome in elderly patients
of DES vs. BMS in small vessel disease.
Methods: From January 2004 to December 2008, all elderly patients
(75 years) treated with stenting of native small coronary arteries (defined as
reference vessel diameter and implanted stent <3 mm) were prospectively
enrolled. According to the type of stent implanted, patients were divided into
BMS and DES group. Procedural and long-term clinical outcomes were com-
pared between both groups. 
Results: A total of 293 patients were enrolled (175 treated with BMS, 118
with DES). Clinical follow up was obtained in 96.2% (median follow-up 3.7
± 1.4 years). At five years, patients treated with DES showed significantly
lower major adverse cardiac events (MACE) (HR 0.42, 95%CI 0.24-0.72, log-
rank P=0.002) and target vessel revascularization (TVR) (HR 0.33, 95%CI
0.14-0.76, log-rank P=0.009). No significant differences were observed
between the two groups as to death, myocardial infarction and stent throm-
bosis.
Conclusion: In this real-world registry of small vessel disease, DES was
safe and more effective than BMS in reducing MACE and TVR at 5 years in
elderly patients.
TVF according to the type of stent
